Treating skin graft donor sites: a comparative study between remnant skin use and polyurethane foam

Abstract

Objective: Excess remnant skin is retained for use in additional grafting in case of split-thickness skin graft (STSG) failure. We hypothesise that regrafting with remnant skin offers greater efficacy and advantages in wound healing and donor site appearance. Methods: Skin graft donor sites were assessed by comparing those regrafted with remnant skin with those treated with polyurethane foam dressing. Healing time, pain, patient satisfaction, itching sensation, skin stiffness and irregularity between regrafting and foam dressing were compared. The aesthetic satisfaction of donor site was evaluated by four board-certified plastic surgeons. The differences were tested statistically. Results: A total of 39 patients received a STSG due to skin or soft tissue wounds caused by burn, trauma and cancer reconstruction. The donor site healing time was shorter with remnant skin regrafting compared with foam dressing. There was no difference with respect to donor site pain between the two treatment groups. At two weeks after skin graft, patient satisfaction was higher in those treated with remnant skin than in those treated with foam dressing. Aesthetic assessment was improved after 12 weeks. Conclusion: Donor site dressing using remnant skin appears to improve wound healing and enhance the aesthetic outcome of donor sites.

Evaluation of amnion versus calcium alginate as split-thickness skin graft donor site dressing: A randomised controlled trial

“…been reached so far. [11][12][13][14][15][16][17] The ideal split-thickness skin graft donor site dressing should be comfortable, not require repeated dressing changes, promote healing and avoid the long-term complication of hypertrophy. [18][19][20][21][22] To the best of our knowledge, this study is unique as there has been no previous study on indexed English literature review comparing the effectiveness of amnion versus calcium alginate on split-thickness skin graft donor sites.…”